摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[4-[[1-(1,2,3,4-tetrahydro-8-quinolinyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone | 317594-59-5

中文名称
——
中文别名
——
英文名称
1-[4-[[1-(1,2,3,4-tetrahydro-8-quinolinyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone
英文别名
3-methyl-1-[4-[[1-(1,2,3,4-tetrahydroquinolin-8-yl)benzimidazol-2-yl]amino]piperidin-1-yl]butan-2-one
1-[4-[[1-(1,2,3,4-tetrahydro-8-quinolinyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone化学式
CAS
317594-59-5
化学式
C26H33N5O
mdl
——
分子量
431.581
InChiKey
WQCNDKBJXDCPGU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.2
  • 重原子数:
    32
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    62.2
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    1-[4-[[1-(8-quinolinyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone 、 苄胺 氢气二氯甲烷甲醇 、 residue 、 methanol-dichloromethane 、 Dichloromethane methanol ammonium hydroxide 作用下, 以 甲醇 为溶剂, 40.0 ℃ 、40.0 MPa 条件下, 反应 48.0h, 以yielding 2.6 g 1-[4-[[1-(1,2,3,4-tetrahydro-8-quinolinyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone (interm. 40) (fraction 1), 2.9 g of fraction 2 and 0.7 g of fraction 3的产率得到1-[4-[[1-(1,2,3,4-tetrahydro-8-quinolinyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl-2-butanone
    参考文献:
    名称:
    Respiratory syncytial virus replication inhibitors
    摘要:
    本发明涉及公式(I)的化合物,前药,N-氧化物,加成盐,季铵盐,金属配合物和立体化学异构体,其中-a1 = a2-a3 = a4-表示公式—CH = CH-CH = CH-;—N = CH-CH = CH-;—CH = N-CH = CH-;—CH = CH-N = CH-; CH = CH-CH = N-;其中每个氢原子可以选择被取代;Q是公式(b-1),(b-2),(b-3),(b-4),(b-5),(b-6),(b-7)和(b-8)的基团,其中Alk是C1-6烷基二亚基;Y1是公式—NR2—或—CH(NR2R4)的双价基团;X1是NR4,S,S(═O),S(═O)2,O,CH2,C(═O),CH(═CH2),CH(OH),CH(CH3),CH(OCH3),CH(SCH3),CH(NR5aR5b),CH2—NR4或NR4—CH2;X2是直接键,CH2,C(═O),NR4,C1-4烷基-NR4,NR4—C1-4烷基,t为2至5;u为1至5;v为2或3;其中Alk和(b-3),(b-4),(b-5),(b-6),(b-7)和(b-8)中的每个氢可以选择被R3取代;但是当R3为羟基或C1-6烷氧基时,R3不能取代氮原子相对的α位置上的氢原子;G是直接键或可选择取代的C1-10烷基二亚基;R1是可选择取代的双环杂环;R2是氢,甲酰基,C1-6烷基羰基,Hetcarbonyl,吡咯烷基,哌啶基,同半哌啶基,C3-7环烷基或C1-10烷基,其被N(R6)2和可选择另一个取代基取代;R3是氢,羟基,C1-6烷基,C1-6烷氧基,芳基C1-6烷基或芳基C1-6烷氧基;R4是氢,C1-6烷基或芳基C1-6烷基;R5a,R5b,R5c和R5d是氢或C1-6烷基;或R5a和R5b,或R5c和R5d一起形成公式—(CH2)S—的双价基团,其中S为4或5;R6是氢,C1-4烷基,甲酰基,羟基C1-6烷基,C1-6烷基羰基或C1-6烷氧羰基;芳基是可选择取代的苯基;Het是吡啶基,嘧啶基,吡啶啉基,吡嗪啉基;作为呼吸道合胞病毒复制抑制剂;它们的制备,含有它们的组合物以及它们作为药物的用途。
    公开号:
    US20060058309A1
点击查看最新优质反应信息

文献信息

  • RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS
    申请人:JANSSEN PHARMACEUTICA N.V.
    公开号:EP1196410B1
    公开(公告)日:2004-02-18
  • US7071192B1
    申请人:——
    公开号:US7071192B1
    公开(公告)日:2006-07-04
  • US7407969B2
    申请人:——
    公开号:US7407969B2
    公开(公告)日:2008-08-05
  • [EN] RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS<br/>[FR] INHIBITEURS DE RÉPLICATION DE VIRUS SYNCYTIAUX RESPIRATOIRES
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2001000615A1
    公开(公告)日:2001-01-04
    The present invention concerns compounds of formula (I), prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof wherein -a?1=a2-a3=a4¿- represents a radical of formula -CH=CH-CH=CH-; -N=CH-CH=CH-; -CH=N-CH=CH-; -CH=CH-N=CH-; -CH=CH-CH=N-; wherein each hydrogen atom may optionally be substituted; Q is a radical of formulae (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8), wherein Alk is C¿1-6?alkanediyl; Y?1¿ is a bivalent radical of formula -NR2- or -CH(NR?2R4)-; X1 is NR4¿, S, S(=O), S(=O)¿2?, O, CH2, C(=O), CH(=CH2), CH(OH), CH(CH3), CH(OCH3), CH(SCH3), CH(NR?5aR5b), CH¿2-NR?4 or NR4-CH¿2; X2 is a direct bond, CH¿2?, C(=O), NR?4, C¿1-4alkyl-NR?4, NR4-C¿1-4alkyl, t is 2 to 5; u is 1 to 5; v is 2 or 3; and whereby each hydrogen in Alk and in (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8), may optionally be replaced by R3; provided that when R3 is hydroxy or C¿1-6?alkyloxy, then R?3¿ cannot replace a hydrogen atom in the α position relative to a nitrogen atom; G is a direct bond or optionally substituted C¿1-10?alkanediyl; R?1¿ is an optionally substituted bicyclic heterocycle; R2 is hydrogen, formyl, C¿1-6?alkylcarbonyl, Hetcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, C3-7cycloalkyl or C1-10alkyl substituted with N(R?6)¿2 and optionally with another substituent; R3 is hydrogen, hydroxy, C¿1-6?alkyl, C1-6alkyloxy, arylC1-6alkyl or arylC1-6alkyloxy, R?4¿ is hydrogen, C¿1-6?alkyl or arylC1-6alkyl; R?5a, R5b, R5c and R5d¿ are hydrogen or C¿1-6?alkyl; or R?5a and R5b, or R5c and R5d¿ taken together from a bivalent radical of formula -(CH¿2?)s- wherein S is 4 or 5; R?6¿ is hydrogen, C¿1-4?alkyl, formyl, hydroxyC1-6alkyl, C1-6alkylcarbonyl or C1-6alkyloxycarbonyl; aryl is optionally substituted phenyl; Het is pyridyl, pyrimidinyl, pyryzinyl, pyridazinyl; as respiratory syncytial virus replication inhibitors; their preparation, compositions containing them and their use as a medicine.
查看更多